   Program Abstracts |
1994
Greenford, UK
| COST-Bl Working Party on Population Approaches: L.Aarons(1), L.P.Balant(2), F.Mentre(3), P.L.Morselli(4), M.Rowland(1), J.-L.Steimer(5), and S.Vozeh(6) Population Approaches in Drug Development: Report on an expert meeting to discuss population pharmacokinetic/pharmacodynamic software |
| Athanassios Iliadis APIS : A software for clinical and experimental pharmacokinetics |
| Saik Urien MicroPharm Population (MP2) - An interactive and user-friendly interfaced program for population pharmacokinetics. |
| Xavier Barbaut (1,2), Roger W. Jelliffe (2), Pascal Maire (1,2), Alan Schumitzky (2), Michael van Guilder (2), Bruno Charpiat (1) NPEM2: A Nonparametric Program Useful For Clinical Uses : Both Population Pharmacokinetic Modeling, Leading To “Multiple Model” (MM) Adaptive Control |
| R.Gomeni P-PHARM: A Population Pharmacokinetic-Pharmacodynamic Data Modeling Software |
| Jon Wakefield POPKAN - Population Pharmacokinetic Analysis using Bayesian Inference |
| Y. Merlé, F. Mentré, J. Gilles and A. Mallet. The Nonparametric Maximum Likelihood Method (NPML) |
| Mats O. Karlsson Stability Of Covariate Models |
| L. Claret, A. Iliadis. Non-Parametric Density Estimation Applied To Population Studies |
| 0. Petricoul(1,2), A. Iliadis(1), L. Claret(1). C. Puozzo(2) Information Theory in Drug Development. Applications to a new antidepressant. |
| B.Charpiat(1), N.Laurent(1), J.M.Sab(2), V.Breant(1), C.Ducerf(3), S.Tigaud(4), D.Robert(2), R.W.Jelliffe(5) Cyclosporine Population Pharmacokinetic Parameters In The Early Postoperative Hepatic Transplantation Phase: Preliminary Results |
| James Bennett and Jon Wakefield Covariate Identification for Population Pharmacokinetic Modelling |
| S. Walker, J.C. Wakefield Population analysis of a dose ranging study |
| E.M. Parker, M. Hutchison Pharmacokinetics of Meropenem in pediatrics - NONMEM analysis |
| P Burtin (1,3), E Jacqz-Aigrain (1), P Girard (2) Population pharmacokinetics of midazolam in neonates |
| Dinesh de Alwis(1), Leon Aarons(1) and Jonathan Palmer(2) The Population Pharmacokinetics of Ondansetron from Phase 1 Studies |
| A.C.Falcao(1,2), M.M.Fernandez de Gatta, M.F.Delgado Iribarnegaray, D.Santos Buelga, M.J.Garcia, A.Dominguez-Gil, J.M.Lanao Caffeine Pharmacokinetics In a Pediatric Population |
| C. Laveille Pharm.D., M. Malbezin M.D, D. Guez M.D., R. Jochemsen Ph.D. Pharmacokinetics Of S-12024 By A Prospective Population Approach In Phase II. |
| Valérie Cosson, Pharm D(1), Pr Jean-Michel Scherrmann(2), ElianeFuseau,PhD(1) Population Pharmacokinetics Of Oral Sumatriptan |
| S.F. Marshall, H.L. Elliott, P.A. Meredith. A Population Approach to Dose Versus Response Relationship For Simvastatin in Hypertensive Hypercholesterolaemic Patients. |
| Lacey LF(1), Kler L.(2) Effect of covariatcs on steady-state trough plasma bismuth concentrations from GR122311X in duodenal ulcer patients. |
| M. Tod, C. Pobel, O. Petitjean, N. Brion, J. Garcia-Mace A Population Pharmacokinetic Study Of Alminoprofen Penetration Into Synovial Fluid |
| M.Tod, J.M. Rocchisani Optimal Sampling Times Determination By Criteria Incorporating Knowledge Of Parameter Distribution In The Population |
| Niclas Jonsson, Janet R. Wade and Mats O. Karlsson Comparison of Practical Sampling Strategies for Population Pharmacokinetic Studies |
| Lynne Evans, Leon Aarons Use of the EM algorithm in population pharmacokinetic analysis |
| M.T. Mateu; J.J. Perez-Ruixo; V.G. Casabo; N.V. Jimenez Estimation of Population Pharmacokinetic Parameters of Tobramycin in Intensive Care Unit Patients Using Different Programs |
| D. Breilh, C. Pobel, L. Lagagnier, P. Maire, M.C. Saux Evaluation Of Bayesian Estimators For Adaptative Control Of Vancomycin Built With Two Methods Of Population Modeling |
| Markus Jerling(1) , Yann Merlé(2) , France Mentré(2) and Alain Mallet(2) Population pharmacokinetics of nortriptyline at monotherapy and during concomitant treatment with drugs that inhibit CYP2D6; an evaluation with the nonparametric maximum likelihood method |
| Carl Peck, Tom Ludden Pitfalls in Retrospective Analysis in Search of Concentration-Effect Relationships |
| Mats O. Karlsson(1,3), Stuart L. Beal(2) and Lewis B. Sheiner(1,2) Three New Residual Error Models For Population PK/PD Analyses |
| J.R. Wade, PhD(1,2), S.L. Beal PhD(2) and N.C. Sambol, PharmD(2) Interaction between structural, statistical and covariate models in population pharmacokinetic analysis |
| Jaap W Mandema(1), Davide Verotta(2), and Lewis B Sheiner(2,3) Diagnostics For Nonlinear Mixed Effects Models |
| Y. Merlé and F. Mentré Comparison of Bayesian Optimal Designs with Respect to Variations of the Population Characteristics. For a Pharmacokinetic and a Pharmacodynamic Model |
| Constantin Efthymiopoulos, PhD, Valérie Cosson, Pharm D, Alan Bye, PhD The Use of NONMEM in Interspecies Allometric Scaling |
| Alan V. Boddy, Michael Cole, Peng Bin, Andrew D.J. Pearson and David R. Newell A limited sampling model with Bayesian estimation to determine carboplatin pharmacokinetics in paediatrics |
| E Chatelut(1,2), V Brunner(1), C Chevreau(1), A Pujol(1), H Roché(1), V Paschel(1), G Houin(2), R Bugat(1,2), P Canal(1) Carboplatin Population Pharmacokinetics |
| Dr Alan Bye, Head of Clinical Pharmacokinetics Department Issues and Suggested Solutions in Drug Development |
| René Bruno, N. Vivier, J.C. Vergniol, G. Montay and L.B. Sheiner(1) A Validation For A Population Pharmacokinetic Model For Docetaxel |
| Andrew P. Grieve Combining Studies : Opportunities And Pitfalls |
| Jean-Louis Steimer, Marie-Eve Ebelin Implementation of pharmacometric approaches into clinical drug development ? A prospective view |
| Lewis B. Sheiner, MD The Future Place Of Modeling In Drug Development |
| Jon Wakefield Review of methods |
